Latest news with #DoximityGPT
CNBC
4 days ago
- Business
- CNBC
Doximity buys Pathway Medical for $63 million to help doctors get AI-powered answers
Doximity is diving deeper into artificial intelligence, announcing on Thursday the acquisition of startup Pathway Medical for $63 million. Pathway has built an AI-powered clinical reference tool that doctors can use to ask questions about guidelines, drugs and trials. Pathway's answers are synthesized from medical literature, and Doximity said the Montreal-based startup has one of the largest structured datasets in medicine. Doximity's platform, which for years was described as LinkedIn for doctors, helps clinicians stay current on medical news, manage paperwork, find referrals and carry out telehealth appointments with patients. Through its acquisition of Pathway, Doximity hopes doctors will also turn to the platform to answer their clinical questions. "We hunted high and low, and I think we found the best company in the space at answering physicians' questions using AI, and it wasn't in Silicon Valley," Jeff Tangney, Doximity's co-founder and CEO, told CNBC in an interview. The deal closed in late July for a cash consideration of $26 million and up to $37 million in additional equity grants, Doximity said. Doximity's integration with Pathway is well underway, Tangney said, and the companies are testing a combined product with thousands of doctors. Doximity already has a free AI product, Doximity GPT, that doctors can use to generate insurance letters and summarize patient charts and reports. Pathway will bring additional "robustness" to the data that Doximity has on the back end, said Dr. Amit Phull, Doximity's chief clinical experience officer. "What Pathway brings to this party or this marriage is that they have a very, very robust back-end data set that ties dosages to guidelines to literature to citations," Phull told CNBC in an interview. Pathway's model scored 96% on the U.S. Medical Licensing Examination benchmark, Doximity said, which doctors have to take to prove that they understand and can apply medical knowledge. Doximity, which went public in 2021, has seen its stock climb 8% this year after soaring 90% in 2024. The company has a market cap of about $11 billion. Doximity is holding its quarterly conference call with investors to discuss its fiscal first-quarter results on Thursday at 5 p.m. ET.
Yahoo
11-06-2025
- Business
- Yahoo
DOCS Boosts Client Retention via Workflow Integration and AI Tools
The renowned digital platform for U.S. medical professionals, Doximity, Inc.'s DOCS client engagement and retention strategy is built around deeply integrated, physician-first tools across its Marketing, Hiring and Workflow Solutions. By focusing on clinical utility and streamlining healthcare professionals' day-to-day workflows, the platform has seen high adoption — more than 620,000 unique providers used its clinical tools in the fourth quarter of fiscal 2025. This functional alignment with medical practices enhances relevance and trust, making Doximity an essential platform for providers. DOCS' Marketing Solutions deliver personalized campaigns through newsfeeds, workflow placements and peer messaging modules. Leveraging AI and machine learning, these solutions help pharmaceutical and health system clients reach narrowly defined clinician segments with relevant content. This targeted, data-driven approach consistently delivers measurable engagement, encouraging clients to expand usage across multiple brands or service lines. To reinforce retention, Doximity invests in a strong customer success team that works hands-on with clients to fine-tune campaigns, optimize content and provide ongoing analytics. Clients also have access to a self-serve portal for real-time insights. This approach has helped drive upsell opportunities and long-term client relationships. On the enterprise side, Workflow Solutions like Dialer Enterprise and AMiON have seen significant traction. These tools are now embedded into hospital operations, making transitions away from Doximity less likely. Additionally, recent enhancements such as Doximity GPT, an AI-powered, HIPAA-compliant writing assistant, add further value for clients by reducing administrative burden. This month, GoodRx Holdings, Inc. GDRX launched Community Link, enabling independent pharmacies to directly contract with it using cost-plus pricing. This shift enhances pharmacy engagement by improving pricing control and participation in GoodRx's proprietary offering, Integrated Savings Program. This program plays a key role in the company's efforts to improve pharmacy engagement and retention. Also this month, GoodRx introduced a new erectile dysfunction subscription service — offering virtual consults, transparent pricing and home delivery — streamlining consumer access and promoting recurring use through simplified, stigma-free digital care options. Veeva Systems Inc. VEEV continues to strengthen client engagement through its growing Vault CRM Suite, which unifies medical, sales, and service teams around a shared customer view. In its first-quarter fiscal 2026 results, Veeva Systems highlighted momentum in products like Veeva Link and Crossix, which deliver real-time insights and multichannel engagement metrics. By expanding commercial cloud adoption and investing in data-rich, modular platforms, Veeva Systems reinforces customer stickiness, driving higher retention among top-tier life sciences clients. These innovations support more intelligent, coordinated outreach across the customer journey. Shares of Doximity have gained 9.6% year to date against the industry's loss of 0.9%. Image Source: Zacks Investment Research DOCS' forward 12-month P/E of 39.4X is higher than the industry's average of 14.6X, but is lower than its three-year median of 48.9X. It carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for DOCS' fiscal 2026 earnings per share suggests a 3.5% improvement from fiscal 2025. Image Source: Zacks Investment Research Doximity stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Veeva Systems Inc. (VEEV) : Free Stock Analysis Report GoodRx Holdings, Inc. (GDRX) : Free Stock Analysis Report Doximity, Inc. (DOCS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
Why Doximity Stock Is Plummeting Today
Leading digital healthcare platform Doximity rocketed past analysts' expectations, but offered up disappointing guidance. Trading at a premium valuation, the company sold off as the market fretted over this potentially slowing growth. However, sales from Doximity's AI tools grew fivefold from last year, providing immense long-term potential. These 10 stocks could mint the next wave of millionaires › Shares of the leading digital platform for U.S. medical professionals, Doximity (NYSE: DOCS), were down 14% as of noon ET Friday, according to data provided by S&P Global Market Intelligence. Doximity wrapped up its fiscal 2025 on Friday, delivering revenue and free cash flow (FCF) growth of 20% and 50%, respectively, during the year. These results rocketed past analysts' expectations. However, management's guidance for 10% sales growth in 2026 was shy of the market's hopes, prompting today's sell-off. Considered the "Bloomberg platform for medical professionals," Doximity is dominant in its niche, with 80% of U.S. physicians using its platform. Providing a curated newsfeed, telehealth options, scheduling capabilities, professional networking, and an array of AI-powered workflow solutions, Doximity's platform has become indispensable among healthcare workers. Thanks to this broad reach within the medical community, the company's platform is an attractive asset for pharmaceutical companies and hospital systems looking to market their products and services. Reinforcing this fact, Doximity counts each of the largest 20 pharmaceutical companies and hospital systems as customers. By virtue of this dominant positioning, the company's 43% annualized growth rate over the last five years, and its FCF margin of 47%, Doximity commanded a lofty price-to-FCF ratio of 50 before today's decline. However, since the market had Doximity priced for (or at least, near) perfection, its 10% sales growth guidance was not enough. Despite this, sales from the company's AI tools like Doximity GPT -- which can summarize a patient's healthcare history and search for diagnostic clues -- grew fivefold from last year, indicating immense potential. With the number of customers spending $500,000 or more annually with the company increasing 17%, and existing customers growing sales 19% in 2025, Doximity's land-and-expand model continues firing on all cylinders. Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $349,648!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $40,142!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $635,275!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of May 12, 2025 Josh Kohn-Lindquist has positions in Doximity. The Motley Fool has positions in and recommends Doximity. The Motley Fool has a disclosure policy. Why Doximity Stock Is Plummeting Today was originally published by The Motley Fool
